Company intelligence / Profile preview

Omikron Italia

Ownership
Private
Development stage
Other
01

Overview

Omikron Italia develops and markets pharmaceutical products and innovative therapeutic responses dedicated primarily to patients with major ophthalmic conditions and vascular diseases. The company positions itself as a partner for specialists and general practitioners in these fields. Product details are restricted to registered medical professionals.

Therapeutic areas
OphthalmologyCardiovascular
Modalities
small moleculesnutraceuticals/food supplements
Industry
Biotech
02

Drug pipeline

5 assets

OP-I-03

Preclinical

4 more assets in the full pipeline.

Beyond the preview

Go deeper on Omikron Italia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omikron Italia.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call